<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766857</url>
  </required_header>
  <id_info>
    <org_study_id>DC2008exe001</org_study_id>
    <secondary_id>EudraCT: 2008-005325-10</secondary_id>
    <nct_id>NCT00766857</nct_id>
  </id_info>
  <brief_title>Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure</brief_title>
  <official_title>The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if exenatide will improve global cardiac function
      in patients with type 2 diabetes mellitus and congestive heart failure, by favorable effects
      on cardiac metabolism leading to improvement of cardiac efficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction).</measure>
    <time_frame>week -2 and week 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac oxygen consumption, cardiac efficiency and stress perfusion will be assessed by Positron Emission Tomography (PET) using 11C-acetate and H2-15O</measure>
    <time_frame>week -2 and week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function, dimensions and scarring will be measured bij CMR</measure>
    <time_frame>week -2 and week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial diastolic function parameters will be obtained bij trans thoracal echocardiography. Comparisons will be made of strain and torsion measures obtained bij CMR and echocardiography.</measure>
    <time_frame>week -2 and week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity and performance will be assessed by a 6-minute walking test</measure>
    <time_frame>week -1 and week 27</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>1. Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).</description>
    <arm_group_label>1. Exenatide</arm_group_label>
    <other_name>exenatide-Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.</description>
    <arm_group_label>2. Insulin glargine</arm_group_label>
    <other_name>insulin glargine-Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Male and postmenopausal female

          -  Age 18 years an above

          -  Metformin therapy (stable, maximum tolerable dose for 2 months)

          -  HbA1c 6.5-10%

          -  Confirmed congestive heart failure (NHYA functional class II-IV)

          -  Ejection fraction &lt; 50%

          -  Patients should receive a stable standard therapy for their cardiac condition for 3
             months prior entering the study

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Serious renal or liver impairment

          -  (Receiving treatment for) malignant disease

          -  Cardiovascular event &lt; 3 months prior to inclusion

          -  Acute congestive heart failure

          -  Any reason for not being able to sustain the imaging studies

          -  Pacemaker/ICD

          -  Contraindications for the use of exenatide/ insulin

          -  Use of insulin, thiazolidinediones, incretin-based therapies within 4 months of
             screening

          -  Chronic use of glucocorticoids, NSAIDs or centrally acting drugs (&gt; 2 weeks) within 2
             weeks immediately prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela Diamant, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VUMC Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M.H.H. Kramer</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Exenatide</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Congestive heart failure</keyword>
  <keyword>Incretin hormones</keyword>
  <keyword>GLP-1 agonist</keyword>
  <keyword>Cardiac metabolism</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Cardiac MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

